Healthy INSIDER Podcast 28: Regulatory Discussion of CBD With Hoban Law GroupHealthy INSIDER Podcast 28: Regulatory Discussion of CBD With Hoban Law Group
In this Healthy INSIDER Podcast, Josh Long, INSIDER’s legal and regulatory editor, and cannabis attorney Garrett Graff discuss the regulatory state of the burgeoning CBD market and the industry’s rationale for disagreeing with FDA’s position that the hemp-derived cannabinoid cannot be sold in dietary supplements.
Despite regulatory hurdles, the CBD industry has continued to grow and gain increasing national attention, fueled largely by stories of the cannabinoid’s potential to treat medical conditions, such as rare forms of epilepsy.
While dietary supplements cannot legally treat a disease, producers and marketers of hemp-derived CBD products have nonetheless sought to capitalize on the burgeoning demand for CBD while toeing the line with federal regulators.
In this Healthy INSIDER Podcast, Josh Long, INSIDER’s legal and regulatory editor, and cannabis attorney Garrett Graff discuss:
· The industry’s rationale for disagreeing with FDA’s position that hemp-derived CBD cannot be sold in dietary supplements;
· Measures taken by responsible companies to ameliorate their risks to enforcement actions; and
· Future developments that could provide more certainty for the industry in protecting companies’ investments.
For related coverage on enforcement action taken by FDA against marketers of CBD, check out this blog.
About the Author(s)
You May Also Like
The ashwagandha root production process: Where tradition meets science – article part threeSep 21, 2023
Former FDA employees weigh in on gov’t shutdownSep 27, 2023
HerbalGram celebrates 40 years of bringing ancient herbal traditions back to life in AmericaSep 27, 2023
New science advances probiotics, milk fats and herbsSep 27, 2023